RemeGen Co

RemeGen Co Receivables

The Accounts Receivable of RemeGen Co (688331.SS) as of Oct 26, 2026 is 383.39 M CNY. In the previous year, Accounts Receivable was 297.68 M CNY — a change of 28.79% (higher).

Receivables

383.39 MCNY

YoY

28.79%

Last updated:

Accounts Receivable of RemeGen Co is 2024 383.39 M CNY. Accounts Receivable of RemeGen Co was 2023 297.68 M CNY. It decreases by 28.79% higher compared to the previous year.

The RemeGen Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
11.00 M CNY
Jan 1, 2019
1.10 M CNY
Jan 1, 2020
0.00 CNY
Jan 1, 2021
7.10 M CNY
Jan 1, 2022
202.03 M CNY
Jan 1, 2023
297.68 M CNY
Jan 1, 2024
383.39 M CNY
The RemeGen Co Receivables history
YEARReceivablesYoY
383.39 MCNY+28.79%
297.68 MCNY+47.34%
202.03 MCNY+2,745.50%
7.10 MCNY—
0.00CNY-100.00%
1.10 MCNY-90.00%
11.00 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Accounts Receivable of RemeGen Co is 383.39 M CNY in 2024.

Accounts Receivable of RemeGen Co changed from 297.68 M CNY to 383.39 M CNY, representing a 28.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RemeGen Co

All Key Metrics — RemeGen Co